Barinthus Biotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Barinthus Biotherapeutics plc (BRNS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-61.07-73.455.32-51.11-17.71
Depreciation & Amortization2.602.234.320.600.21
Deferred Income Tax-0.04-3.08-4.34-0.120.00
Stock Based Compensation4.715.069.8816.493.63
Change in Working Capital2.606.17-6.68-3.571.92
Change in Accounts Receivable-2.355.80-5.830.560.48
Change in Accounts Payable0.90-3.381.14-3.530.59
Change in Other Working Capital-0.043.751.161.150.89
Other Operating Activities1.565.0612.2713.820.92
Net Cash from Operating Activities-28.94-50.93-14.43-32.58-11.03
Investing Activities
Capital Expenditures-0.89-5.416.141.15-0.29
Acquisitions0.000.00-0.07-11.770.00
Net Cash from Investing Activities-0.89-5.41-5.75-12.91-0.29
Financing Activities
Debt Repayment0.000.00-0.160.000.00
Common Stock Issued2.162.040.48102.770.00
Other Financing Activities0.00-0.160.000.300.19
Net Cash from Financing Activities2.161.870.33222.7441.44
Summary
Effect of Forex Changes on Cash-2.022.170.19-6.460.00
Net Change in Cash-29.69-52.30-19.86170.7931.83
Cash at Beginning of Period142.09194.39214.0543.270.00
Cash at End of Period112.40-68.39194.39214.050.00
Free Cash Flow-29.83-50.93-20.18-33.73-11.32
Supplemental Disclosures
Interest Paid0.000.000.001.840.00
Income Taxes Paid0.000.000.000.150.00